New Zealand markets closed

Novartis AG (NVS)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
85.85-0.25 (-0.29%)
At close: 04:00PM EST
86.25 +0.40 (+0.47%)
After hours: 06:40PM EST

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Vasant NarasimhanChief Exec. Officer5.61MN/A1976
Mr. Harry KirschChief Financial Officer2.84MN/A1965
Dr. Klaus Moosmayer Ph.D.Chief Ethics, Risk & Compliance Officer1.55MN/A1968
Ms. Karen L. HaleChief Legal Officer2.34MN/A1968
Dr. Robert Kowalski Pharm.D.Chief People & Organization Officer2.1MN/A1968
Mr. Steffen Lang Ph.D.Pres of Operations2.33MN/A1967
Ms. Marie-France TschudinPres of Innovative Medicines International & Chief Commercial Officer2.38MN/A1971
Mr. Victor BultoPres of Innovative Medicines US2.39MN/AN/A
Dr. Shreeram Aradhye M.D.Pres of Global Drug Devel. & Chief Medical Officer2.28MN/A1963
Mr. Aharon Gal Ph.D.Chief Strategy & Growth Officer6.28MN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate governance

Novartis AG’s ISS governance QualityScore as of 1 February 2023 is 1. The pillar scores are Audit: 4; Board: 2; Shareholder rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.